Author:
Solms Alexander,Reinecke Isabel,Fiala-Buskies Sabine,Keunecke Anne,Drenth Henk-Jan,Bruix Jordi,Meinhardt Gerold,Cleton Adriaan,Ploeger Bart
Reference23 articles.
1. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model;Abou-Elkacem;Mol. Cancer Ther.,2013
2. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development;Breimer;Clin. Pharm.,1997
3. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study;Bruix;Eur. J. Cancer,2013
4. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma;Bruix;Gastroenterology,2016
5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献